Pipeline Selector helps you avoid hours of painstaking
research by quickly providing you with an accurate snapshot of a single INN,
including key patents, extensions and data exclusivity expiry for 44 countries
(7 country coverage also available), regulatory issues and key players.
- This Pipeline Selector report covers Nilotinib
- Nilotinib indications: Treatment of Philadelphia chromosome positive chronic myeloid leukaemia, optionally in combination with erythropoietin, G-CSF, hydroxyurea or Anagrelide
- Nilotinib innovator: Novartis (Tasigna)
To Read
the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/nilotinib-key-patent-spc-and-data-exclusivity-expiry-44-country-coverage
Examples of information found in this online report include:
- Includes key patent publications for 44 countries (see list below)
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by country basis
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
- DMF & Paragraph IV filings
- Litigation alerts
- Marketing authorisation holders in selected territories
- Patent risk analysis via graphical display of data from patent filings
- Hyper-linking to crucial patent documents and national registries enabling data verification
The 'Key Patent Indicator' enables
easy identification of key patent, SPC and data protection expiry information
covering 44 countries, including extension details (SPC and national law) for
30 European countries, Australia, Israel, Japan and the USA. (also available
with 44 country coverage):
To
Buy The Copy of This Report Visit
: http://www.marketresearchreports.biz/analysis/168912
Contact
M/s Sheela
90 Sate Street, Suite
700
Albany, NY 12207
USA – Canada Toll
Free: 866-997-4948
No comments:
Post a Comment